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RNA splicing: More clues from spinal muscular atrophy
A. Gregory Matera
Spinal muscular atrophy is caused by mutations in the
SMN1 gene, the product of which is part of a multi-
component complex involved in the assembly of small
nuclear ribonucleoproteins. A recent study indicates
that SMN may also play a role in pre-mRNA splicing.
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Spinal muscular atrophy is a neurodegenerative disorder
which results in the loss of motor neurons from the spinal
cord, causing progressive paralysis in the limbs and trunk,
followed by muscular atrophy [1]. It is an autosomal
recessive disease with a carrier frequency of about 1 in 50,
and is the most common genetic cause of childhood mor-
tality [2]. The recent identification of the gene that is
defective in spinal muscular atrophy — known as survival
motor neurons 1 (SMN1) [3] — has, as one might have
expected, significantly advanced our understanding of the
molecular basis of this disease. Less expected are the
insights into RNA processing that have come from charac-
terization of the protein, SMN, encoded by this gene.
The tissue-specific phenotype observed in spinal
muscular atrophy has, somewhat surprisingly, turned out
to be caused by a defect in a general cellular function —
the assembly of small nuclear ribonucleoproteins
(snRNPs) (reviewed in [4]). Dreyfuss and colleagues [5]
have now found that when a mutant form of SMN is
expressed in cultured cells, it causes a dramatic reorgani-
zation of snRNPs in both the nucleus and the cytoplasm.
Furthermore, the mutant protein has a dominant-negative
effect on pre-mRNA splicing in vitro, suggesting that
SMN also plays an important role in the function, as well
as the biogenesis, of snRNPs. 
The SMN loci
There are actually two closely related SMN genes, located
within a 500 kilobase inverted duplication on human chro-
mosome 5q13 [3]. Deletion of the telomeric copy, SMN1,
results in the disease, whereas similar mutations in the
centromeric copy, SMN2, have no detectable phenotypic
effects [6]. So although their coding regions differ by only
five silent sequence changes, the SMN genes appear not to
be functionally redundant ([7] and references therein).
Notably, there is only one equivalent gene in the mouse
genome, and it is essential: a targeted deletion of the Smn
gene results in embryonic lethality in the homozygous
state [8]. As reviewed last year in these pages [4], the SMN
protein has been found to be part of a large (~300 kDa)
complex of proteins that are involved in the biogenesis of
snRNPs [9,10]. These include ‘SMN interacting proteins’
(SIP1, SIP2 and SIP3) as well as snRNP core components,
collectively called Sm proteins (B, D1–3 and E–G) [9].
Moreover, antibodies against SIP1 inhibit the assembly
and nuclear import of spliceosomal snRNPs [10]. 
In most cell types, SMN protein is distributed diffusely
throughout the cytoplasm (Figure 1), whereas the nuclear
fraction is localised within discrete foci [11]. These nuclear
foci are found adjacent to, or merged with, nuclear
organelles called coiled bodies, and they have thus been
termed ‘gemini of coiled bodies’ or ‘gems’ (reviewed in
[12]). Coiled bodies are characterized by the presence of a
marker protein called p80 coilin, and contain extremely
high concentrations of snRNPs (reviewed in [13]). The
initial phases of snRNP assembly take place in the cyto-
plasm and are mediated by the SMN complex ([10] and
references therein). This complex may then accompany
the assembled snRNPs on their journey to nuclear gems
and coiled bodies. Until recently, however, a functional role
for SMN within the nucleus has not been demonstrated.
A dominant-negative SMN mutation
Although SMN mutations that give rise to spinal muscular
atrophy are recessive, Dreyfuss and colleagues [5] have
now shown that the expression in cultured cells of a
mutant form of SMN with an amino-terminal deletion,
called SMN∆N27, causes a profound reorganization of
splicing snRNPs in the nucleoplasm. This dominant-
negative phenotype is similar to those caused by inhibi-
tion of pre-mRNA splicing [14] or RNA polymerase II
transcription [15], and involves a dramatic enlargement of
nuclear structures that contain splicing snRNPs. In the
latter two cases, the swollen structures correspond to inter-
chromatin granule clusters, commonly called ‘speckles’. In
contrast, the structures undergoing enlargement in the
presence of the SMN∆N27 mutant are apparently not
speckles, because they do not stain with anti-SR protein
epitopes such as SC-35 (G. Dreyfuss, personal communi-
cation). Rather, they appear to be related to coiled bodies
and gems, as typical components such as p80 coilin, SMN,
SIP1, U2 snRNA and Sm proteins are all enriched within
the large structures [5]. 
Interestingly, SMN∆N27 also causes a reorganization of
the cytoplasmic fraction of the SMN and snRNP staining
patterns. Instead of the normal, diffuse localisation of
SMN throughout the cytoplasm, cells expressing
SMN∆N27 display a number of punctate blobs in the
cytoplasm. Most striking is the fact that the cytoplasmic
blobs result from an apparent block in cytoplasmic snRNP
assembly, as they contain U2 snRNA and Sm proteins, but
their snRNAs lack a trimethylguanosine cap. So although
snRNAs within the nuclei of the transfected cells are
trimethylated, those trapped within the cytoplasmic struc-
tures appear to be partially assembled, and are presumably
arrested at a step preceding cap hypermethylation [5]. But
if SMN∆N27 affects only cytoplasmic snRNP assembly,
why are there large structures in the nucleus?
SMN and splicing
Dreyfuss and colleagues [5] reasoned that because
SMN∆N27 causes such a large-scale reorganization of
splicing factors in the nucleus, it might also have domi-
nant effects on pre-mRNA splicing in vitro. Nonetheless,
initial attempts to demonstrate splicing inhibition met
with frustration, as addition of purified SMN∆N27 protein
to in vitro extracts had no effect; further ‘order-of-addition’
experiments, however, did reveal an effect on splicing.
When SMN∆N27 protein or antibodies against the SMN
amino terminus were present during pre-incubation of a
splicing extract with an ATP regenerating system, before
addition of the labeled pre-mRNA substrate, splicing was
completely inhibited [5]. The block to splicing occurred
prior to the first step, as no partially-spliced intermediates
were detected. Control reactions using wild-type SMN or
antibodies against the protein’s carboxyl terminus did not
inhibit, and in some cases actually stimulated, splicing.
These results suggest that SMN, and by inference the
machinery within coiled bodies and gems, participates in
nuclear snRNP function. 
Dreyfuss and colleagues [5] went on to test this idea by
looking at spliceosomal complexes formed in the splicing
extract using native gel electrophoresis. They found that
pre-incubation of the extract in the absence of added
SMN protein resulted in a decreased ability to form
higher-order snRNP complexes in the presence of ATP.
When extracts were supplemented with a 3–5-fold molar
excess of recombinant wild-type SMN protein, the ability
to make these complexes was restored. Pre-incubation
with SMN∆N27 protein apparently allowed formation of
the pre-catalytic A and B complexes, but not catalytically
active spliceosomes (C complexes). Thus, in vitro, SMN is
a limiting reagent in the formation of higher-order com-
plexes, and its amino terminus appears to be somehow
involved in the transition from pre-catalytic to catalytically
active spliceosomes. Dreyfuss and colleagues [5] posit that
SMN∆N27 produces complexes that are trapped in a non-
functional state, and that wild-type SMN may participate
in regeneration of ‘used’ splicing factors. 
While the above scenario may certainly be correct, the
data are consistent with a number of alternative hypothe-
ses. For example, it is possible that SMN protein may not
actually function in splicing in vivo — it may simply
contain motifs present in bona fide spliceosome
components, and when SMN is overexpressed in vitro
these shared motifs result in displacement of the related
proteins or sequestration of their binding partners. Inter-
estingly, database analysis reveals the existence of a puta-
tive SMN-related splicing factor: SPF-30, a protein
identified as part of a large-scale characterization of
spliceosomal proteins [16], has a region of significant
similarity to SMN, in addition to a number of highly
conserved residues throughout the length of the protein.
Additional experiments will be required in order to
exclude this and other possibilities, and improve our
understanding of the nature of the dominant-negative
effect of SMN∆N27.
Although the precise function of the amino-terminal
region of SMN is unclear, it is perhaps noteworthy that
regions of the protein that interact with SIP1 and SmB [9]
are not affected by the 27 amino-acid truncation in
SMN∆N27. Curiously, wild-type Xenopus SMN protein
has the same dominant-negative effect when expressed in
human cells (G. Dreyfuss, personal communication), and
alignment of the human and frog proteins reveals that the
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Figure 1
In HeLa cells, SMN protein is localized throughout the cytoplasm but
present in several bright foci within each nucleus. The protein was
revealed by staining with monoclonal antibody 2B1 (gift of G.
Dreyfuss); the cells were permeabilized with Triton-X 100 after fixation
in paraformaldehyde.  The bright nuclear foci are completely coincident
with p80 coilin staining (see [12] for discussion). Overexpression of
the mutant form SMN∆N27 causes these structures to become greatly
enlarged — to nearly the same size as nucleoli — and has dominant-
negative effects on pre-mRNA splicing in vitro [5].
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frog protein lacks these amino-terminal residues. These
observations suggest that the amino terminus of human
SMN is required for some event, perhaps a conformational
change, that is necessary for the production of active
spliceosomes. Thus, while the multi-snRNP complexes
that form in the presence of SMN∆N27 may migrate on
gels at a position similar to intact spliceosomes, they may
actually be ‘dead-end’ complexes, unable to participate in
splicing or serve as substrates for disassembly. 
As with most provocative research endeavours, the results
reported by Dreyfuss and colleagues [5] actually generate
more questions than they answer. Future research on the
roles of SMN protein, gems and coiled bodies in the bio-
genesis and functions of small RNPs should bring new
insights into the cell biology of the nucleus, especially the
metabolic processes that take place within the various
subdomains and their relevance to the treatment of molec-
ular diseases such as spinal muscular atrophy. 
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